Oncology

Cambrex takes over Avista in USD 250 Million agreement Cambrex, life sciences company, is taking over Avista Pharma Solutions with a deal of USD 250 million to become a leading contract development and manufacturing organization (CDMO). The agreement includes the early-stage drug development and manufacturing capabilities of Avista to, New Jersey-based, Cambrex's existing active pharmaceutical ingredient and finished dosage form services. Sobi pays USD 50 Million on a rare disease drug After Sobi remunerated Novimmune with USD 50 million in cash and used USD 400 million in milestones for a rare disease drug called emapalumab.  The FDA has given a nod to it. The drug i...